DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017
(Thomson Reuters ONE) -
Press Release
Montrouge, France, May 8, 2017
DBV Technologies Highlights Research Presentation of EPIT(®) for the Treatment
of Crohn's Disease at Digestive Disease Week 2017
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced the presentation of a preclinical poster highlighting the
therapeutic potential of epicutaneous immunotherapy (EPIT) in inflammatory
gastrointestinal diseases at Digestive Disease Week (DDW) in Chicago, Illinois,
May 6-9, 2017.
The poster (Su1838), entitled "Tolerance with Viaskin requires TGF-b and can be
utilized as a Treatment of Intestinal Inflammation in Murine Models," was
accepted as a Poster of Distinction and presented by Dr. David Dunkin,
Department of Pediatric Gastroenterology and The Mindich Child Health and
Development Institute, The Icahn School of Medicine at Mount Sinai, New York,
NY, on Sunday, May 7, from 12-2 pm CT.
In this preclinical study, epicutaneous treatment with a 100 µg dose of Viaskin-
Ovalbumin was associated with the induction of ovalbumin-specific regulatory T
cells (Tregs) migrating to the gut and abrogating colitis and ileitis in mice
via bystander suppression. EPIT was observed to increase Foxp3, LAP+ Tregs and
TGF-b secretion in animal models, supporting the potential clinical application
of EPIT in the treatment of Crohn's disease.
In February 2014, DBV Technologies and The Icahn School of Medicine at Mount
Sinai entered into a research collaboration to investigate the use of the
Viaskin technology for the treatment of Crohn's disease. In December 2015,
additional preclinical data supporting Viaskin's application in Crohn's was
presented at the Crohn's & Colitis Foundation of America Advances in
Inflammatory Bowel Diseases (AIBD) meeting in Orlando, Florida.
About Crohn's disease
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract,
mainly characterized by abdominal pain, diarrhea and various digestive and non-
digestive complications. There are no medications or surgical procedures that
can cure Crohn's disease. One in five people with Crohn's are admitted to a
hospital each year, and as many as half of those suffering from the disease will
require surgery over a ten-year period. The incidence of Crohn's is increasing,
especially in young children and infants. Both men and women can be affected by
Crohn's disease, which is usually diagnosed between the ages of 15 - 30.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates,
including statements regarding the potential of Viaskin to treat Crohn's
disease. These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this stage, the
products of the Company have not been authorized for sale in any country. Among
the factors that could cause actual results to differ materially from those
described or projected herein include uncertainties associated generally with
research and development, clinical trials and related regulatory reviews and
approvals and the risk that historical preclinical results may not be predictive
of future clinical trial results. A further list and description of these risks,
uncertainties and other risks can be found in the Company's regulatory filings
with the French Autorité des Marchés Financiers, the Company's Securities and
Exchange Commission filings and reports, including in the Company's Annual
Report on Form 20-F for the year ended December 31, 2016 and future filings and
reports by the Company. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements and estimates, which
speak only as of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release.
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF Version:
http://hugin.info/156437/R/2102420/797300.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2017 - 07:31 Uhr
Sprache: Deutsch
News-ID 540725
Anzahl Zeichen: 6771
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
